Meeting at the European Medicine Agency (EMA)

Dr Arechavala-Gomeza will be attending a meeting intended to be a forum discussion between stakeholders on current challenges that face antisense oligonucleotide therapy development for DMD: ‘Antisense oligonucleotide-mediated exon skipping therapy development for Duchenne muscular dystrophy (DMD)’.

This workshop is hosted by the European Medicine Agency (EMA) and organized by COST Action BM1207 and SCOPE-DMD and will be streamed live online via Ustream on Wednesday 29 April from 10 am (Central European Time): ; (password EMA2015).

Bookmark the permalink.

Comments are closed.